 Part 1, any phase of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Part 2, whose disease is resistantrefractory to full-dose imatinib 400 mg for chronic phase subjects600 mg for advanced leukemia subjects, or are intolerant of any dose of imatinib. 